Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response?

Elias Jabbour, Hagop M. Kantarjian, Susan O'Brien, Jianqin Shan, Alfonso Quintás-Cardama, Guillermo Garcia-Manero, Mary Beth Rios, Jorge E. Cortes

Research output: Contribution to journalArticle

53 Scopus citations

Fingerprint Dive into the research topics of 'Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response?'. Together they form a unique fingerprint.

Medicine & Life Sciences